
- /
- Supported exchanges
- / US
- / DXCM.NASDAQ
DexCom Inc (DXCM NASDAQ) stock market data APIs
DexCom Inc Financial Data Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get DexCom Inc data using free add-ons & libraries
Get DexCom Inc Fundamental Data
DexCom Inc Fundamental data includes:
- Net Revenue: 4 148 M
- EBITDA: 858 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-23
- EPS/Forecast: 0.3284
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DexCom Inc News

DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock.
DexCom’s decision to pursue the Type 2 diabetes market wasn’t faulty. It was management’s execution of its strategy that caused the problem. Continue Reading


DXCM Quantitative Stock Analysis
Below is Validea's guru fundamental report for DEXCOM, INC. (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of Part...

What You Need to Know Ahead of DexCom’s Earnings Release
Dexcom Inc HQ-by JHVEPhoto via Shutterstock DexCom, Inc. (DXCM), a San Diego-based medical device company with a $32.5 billion market cap, specializes in continuous glucose monitoring (CGM) systems....

Medtronic's SWOT analysis: stock poised for growth amid challenges
Medtronic PLC (NYSE:MDT), a leading global medical technology company with a market capitalization of $113.25 billion, has been navigating a complex landscape of opportunities and challenges in recen...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.